Rallis Dimitrios, Papathanasiou Aimilia Eirini, Christou Helen
Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Neonatal Intensive Care Unit, University of Ioannina, Faculty of Medicine, Ioannina 45110, Greece.
J Endocr Soc. 2024 Feb 20;8(4):bvae031. doi: 10.1210/jendso/bvae031. eCollection 2024 Feb 19.
In utero exposure to maternal obesity or diabetes is considered a pro-inflammatory state.
To evaluate whether cord blood proprotein convertase subtilisin/kexin-type 9 (PCSK9), which is regulated by inflammation and metabolic derangements, is elevated in neonates born to overweight, obese, or diabetic mothers.
A retrospective study in full-term neonates born between 2010 and 2023, at Brigham and Women's Hospital. There were 116 neonates included in our study, of which 74 (64%) were born to overweight/obese mothers and 42 (36%) were born to nonoverweight/nonobese mothers.
Neonates born to overweight/obese mothers had significantly higher cord blood concentrations of PCSK9 compared with neonates born to nonoverweight/nonobese group (323 [253-442] ng/mL compared with 270 [244-382] ng/mL, = .041). We found no significant difference in cord blood concentrations of PCSK9 between neonates of diabetic mothers compared with neonates of nondiabetic mothers. In multivariate linear regression analysis, higher cord plasma PCSK9 concentration was significantly associated with maternal overweight/obesity status (b = 50.12; 95% CI, 4.02-96.22; = .033), after adjusting for gestational age, birth weight, male sex, and intrauterine growth restriction.
Neonates born to mothers with overweight/obesity have higher cord blood PCSK9 concentrations compared with the nonoverweight/nonobese group, and higher cord blood PCSK9 concentrations were significantly associated with maternal overweight/obesity status, after adjusting for perinatal factors. Larger longitudinal studies are needed to examine the role of PCSK9 in the development of metabolic syndrome in high-risk neonates born to overweight, obese, or diabetic mothers.
子宫内暴露于母亲肥胖或糖尿病被认为是一种促炎状态。
评估受炎症和代谢紊乱调节的脐带血前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）在超重、肥胖或糖尿病母亲所生新生儿中是否升高。
在布莱根妇女医院对2010年至2023年出生的足月新生儿进行一项回顾性研究。我们的研究纳入了116名新生儿，其中74名（64%）由超重/肥胖母亲所生，42名（36%）由非超重/非肥胖母亲所生。
与非超重/非肥胖组母亲所生新生儿相比，超重/肥胖母亲所生新生儿的脐带血PCSK9浓度显著更高（分别为323[253 - 442]ng/mL和270[244 - 382]ng/mL，P = 0.041）。我们发现糖尿病母亲所生新生儿与非糖尿病母亲所生新生儿的脐带血PCSK9浓度无显著差异。在多变量线性回归分析中，调整胎龄、出生体重、男性性别和宫内生长受限后，脐带血浆PCSK9浓度升高与母亲超重/肥胖状态显著相关（b = 50.12；95%置信区间，4.02 - 96.22；P = 0.033）。
与非超重/非肥胖组相比，超重/肥胖母亲所生新生儿的脐带血PCSK9浓度更高，且在调整围产期因素后，脐带血PCSK9浓度升高与母亲超重/肥胖状态显著相关。需要更大规模的纵向研究来检验PCSK9在超重、肥胖或糖尿病母亲所生高危新生儿代谢综合征发展中的作用。
